Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma
(2009)
Authors:
Brunello, A.; Saia, G.; Bedogni, Alberto; Scaglione, D.; Basso, U.
Title:
Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma
Year:
2009
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Referee:
Sì
Name of journal:
Bone
ISSN of journal:
8756-3282
Page numbers:
173-175
Keyword:
osteonecrosis; jaw; sunitinib; cancer
Short description of contents:
We report on the potential association of suspected bisphosphonate-associated osteonecrosis of the jaw
(BRONJ) recurrence with the use of the novel antiangiogenic drug sunitinib. A 59 year-old patient affected by
metastatic renal cell carcinoma (RCC) and established BRONJ experienced consecutive episodes of painful jaw
infection with cutaneous fistula and bone sequestration which occurred during active treatment with
sunitinib, improved after discontinuation and antibiotic therapy, then rapidly worsened with resumption of
sunitinib. We hypothesize that the potent antiangiogenic activity of sunitinib may amplify the inhibition of
bone remodeling exerted by aminobisphosphonates entrapped within the osteonecrotic mineral matrix,
antagonize mucosal healing and expose to infections during treatment. This supports the emerging role of
soft-tissue damage in the pathogenesis of osteonecrosis of the jaw.
Product ID:
51455
Handle IRIS:
11562/334274
Deposited On:
March 29, 2012
Last Modified:
November 14, 2022
Bibliographic citation:
Brunello, A.; Saia, G.; Bedogni, Alberto; Scaglione, D.; Basso, U.,
Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma«Bone»
, 2009
, pp. 173-175